600276 恒瑞医药
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)14.44114.73910.99110.72813.831
总资产报酬率 ROA (%)12.85113.4939.9889.57012.245
投入资产回报率 ROIC (%)13.96314.57210.64810.33213.551

边际利润分析
销售毛利率 (%)86.20786.24984.55283.61285.556
营业利润率 (%)28.42326.76721.51619.32718.007
息税前利润/营业总收入 (%)26.24423.57418.35616.44015.936
净利润/营业总收入 (%)24.39822.64518.74617.93217.309

收益指标分析
经营活动净收益/利润总额(%)98.03397.30798.68388.90592.080
价值变动净收益/利润总额(%)1.0721.575-2.30211.6895.590
营业外收支净额/利润总额(%)-3.243-4.476-5.202-3.615-4.445

偿债能力分析
流动比率 (X)8.0849.71912.2528.5008.875
速动比率 (X)7.6329.05411.3467.8278.168
资产负债率 (%)11.5518.0696.2849.3419.409
带息债务/全部投入资本 (%)2.428-0.0540.9724.0481.586
股东权益/带息债务 (%)3,910.016-184,059.23510,140.5082,350.5206,155.215
股东权益/负债合计 (%)759.2111,125.2271,470.724955.631947.456
利息保障倍数 (X)-20.398-11.518-8.756-7.428-12.216

营运能力分析
应收账款周转天数 (天)57.25965.02587.44489.03867.442
存货周转天数 (天)218.490221.301243.282250.552201.115